01.12.20: not for release, publication or distribution in any jurisdiction in which such release, publication or distribution would be unlawful
Bayer announces placement of Elanco shares for gross proceeds of 1.6 billion U.S. dollars at completionmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - December 1, 2020 Category: Pharmaceuticals Source Type: news
17.11.20: Not intended for U.S. and UK Media - Late-Breaking Data from subgroup analysis of Phase III FIDELIO-DKD study presented at the American Heart Association (AHA) Scientific Sessions 2020
Finerenone showed consistent benefits on cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes with or without history of cardiovascular diseaseIn the FIDELIO-DKD Phase III study among patients with chronic kidney disease and type 2 diabetes, overall finerenone significantly lowered the combined risk of cardiovascular events, with comparable treatment efficacy for patients with or without history of cardiovascular disease / People with chronic kidney disease and type 2 diabetes are three times more likely to die from a cardiovascular-related cause than those with type 2 diabetes alone / Finere...
Source: Bayer IR Newsfeed: Events - November 17, 2020 Category: Pharmaceuticals Source Type: news
13.11.20: Not intended for U.S. and UK Media
Positive CHMP opinion for extension of rivaroxaban marketing authorization to treat venous thromboembolism (VTE) in childrenPediatric patients currently have limited therapeutic options and until now, there have been no approved oral treatments because of the absence of appropriate clinical trials / After approval, rivaroxaban would be the only oral Factor Xa Inhibitor authorized to treat VTE and prevent VTE recurrence in children / An oral suspension of rivaroxaban that does not require injections or regular monitoring has been developed to facilitate pediatric administration / CHMP opinion is based on the largest pediatr...
Source: Bayer IR Newsfeed: Events - November 13, 2020 Category: Pharmaceuticals Source Type: news
12.11.20: Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund
Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt FundMetagenomi is a genomic medicines company pioneering precision gene editing systems to advance curative therapies for oncology and genetic diseases / Proprietary and wholly owned gene editing platform offers the potential to expand the range of treatable diseases and to improve patient access to cell and gene therapiesmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 12, 2020 Category: Pharmaceuticals Source Type: news
09.11.20: Not intended for U.S. and UK Media
Bayer submits marketing authorization applications for finerenone in the U.S. and the EU for patients with chronic kidney disease and type 2 diabetesRegulatory submissions based on positive data from Phase III FIDELIO-DKD study recently published in the New England Journal of Medicinemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 10, 2020 Category: Pharmaceuticals Source Type: news
05.08.21: 2021 Half-Year Report
2021 Half-Year ReportLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 3, 2020 Category: Pharmaceuticals Source Type: news
03.11.20: Bayer:
Challenging third quarter - Group outlook confirmedGroup sales decrease by 5.1 percent (Fx & portfolio adj.) to 8.506 billion euros / EBITDA before special items falls 21.4 percent to 1.795 billion euros / Substantial decline in sales and earnings at Crop Science, heavily impacted by seasonal and currency effects / Pharmaceuticals business recovering - higher earnings but slightly lower sales / Strong performance at Consumer Health / Net loss of 2.744 billion euros - impairment charges at Crop Science, proceeds from divestment of Animal Health / Core earnings per share decline by 30.2 percent to 0.81 euros / Free cash flow...
Source: Bayer IR Newsfeed: Events - November 3, 2020 Category: Pharmaceuticals Source Type: news
09.11.20: Redburn Virtual Canada Conference
Redburn Virtual Canada ConferenceLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 30, 2020 Category: Pharmaceuticals Source Type: news
10.11.20: Morgan Stanley Virtual Global Chemicals Conference
Morgan Stanley Virtual Global Chemicals ConferenceLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 30, 2020 Category: Pharmaceuticals Source Type: news
27.10.20: The U.S. EPA announces new 5-year registration for XtendiMax® herbicide, Bayer's low-volatility dicamba product
The U.S. EPA announces new 5-year registration for XtendiMax® herbicide, Bayer's low-volatility dicamba productThe new registration follows launch announcement for XtendFlex® soybeans and enables full potential of industry-leading Roundup Ready® Xtend Crop Systemmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 28, 2020 Category: Pharmaceuticals Source Type: news
27.10.20: Bayer appoints Dr. Christian Rommel as new Head of Pharmaceuticals Research and Development
Bayer appoints Dr. Christian Rommel as new Head of Pharmaceuticals Research and Developmentmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 28, 2020 Category: Pharmaceuticals Source Type: news
26.10.20: Bayer acquires Asklepios BioPharmaceutical to broaden innovation base in cell and gene therapy
Bayer acquires Asklepios BioPharmaceutical to broaden innovation base in cell and gene therapyAcquisition fuels Bayer's cell and gene therapy platform with potential to bring urgently needed treatments to patients across multiple disease areas with high unmet need / AskBio's industry leading AAV-based gene therapy platform already yielding commercial and clinical stage assets with potential of helping larger patient populations / Portfolio includes investigational pre-clinical and clinical stage development candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases such as ...
Source: Bayer IR Newsfeed: Events - October 26, 2020 Category: Pharmaceuticals Source Type: news
23.10.20: Not intended for U.S. and UK Media
FDA approves FoundationOne®CDx as companion diagnostic for Vitrakvi™ (larotrectinib) to aid in identifying NTRK fusion-positive patientsThe companion diagnostic (CDx) approval is part of the global collaboration between Bayer and Foundation Medicine, Inc. for the development and commercialization of next-generation sequencing (NGS)-based companion diagnostics in oncology / Detection of genomic alterations that drive the growth and spread of the tumor can guide treatment decisions for cancer therapies, such as available biomarker driven therapies / FoundationOne®CDx analyzes substitutions, insertion and deletion alt...
Source: Bayer IR Newsfeed: Events - October 24, 2020 Category: Pharmaceuticals Source Type: news
23.10.20: Not intended for U.S. and UK Media - Data from Phase III FIDELIO-DKD study presented at the American Society of Nephrology (ASN)'s Kidney Week 2020
Finerenone significantly reduced renal and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes Finerenone is a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist that demonstrated renal and cardiovascular benefits in patients with chronic kidney disease and type 2 diabetes / Finerenone specifically addresses MR overactivation, a key driver of disease progression / Despite guideline-directed therapies, patients with chronic kidney disease and type 2 diabetes remain at high risk of progression to kidney failure and cardiovascular events / Results...
Source: Bayer IR Newsfeed: Events - October 23, 2020 Category: Pharmaceuticals Source Type: news
03.11.20: News Conference Call Third Quarter 2020 Results
News Conference Call Third Quarter 2020 ResultsLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 21, 2020 Category: Pharmaceuticals Source Type: news
